Results 161 to 170 of about 309,133 (299)

Short-Term Arrhythmia Prediction Using AI Based on Daily Data From Implantable Devices: Multicenter Prospective Observational Study. [PDF]

open access: yesJMIR Cardio
Fernández Lozano I   +14 more
europepmc   +1 more source

Fetal arrhythmias

open access: yesJournal of the American College of Cardiology, 1987
openaire   +2 more sources

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves   +8 more
wiley   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz   +15 more
wiley   +1 more source

Conduction System Pacing-Induced Ventricular Arrhythmia: Case Report. [PDF]

open access: yesAnn Noninvasive Electrocardiol
Kesriklioglu S   +5 more
europepmc   +1 more source

Cardiac Arrhythmias

open access: yesJournal of the American College of Cardiology, 2006
openaire   +2 more sources

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy